ANDROID 5 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Android 5, and what generic alternatives are available?
Android 5 is a drug marketed by Valeant Pharm Intl and is included in one NDA.
The generic ingredient in ANDROID 5 is methyltestosterone. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Android 5
A generic version of ANDROID 5 was approved as methyltestosterone by IMPAX LABS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANDROID 5?
- What are the global sales for ANDROID 5?
- What is Average Wholesale Price for ANDROID 5?
Summary for ANDROID 5
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 57 |
| Clinical Trials: | 10 |
| Patent Applications: | 4,503 |
| DailyMed Link: | ANDROID 5 at DailyMed |
Recent Clinical Trials for ANDROID 5
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital of North Norway | Phase 4 |
| St. Olavs Hospital | Phase 4 |
| Oslo University Hospital | Phase 4 |
US Patents and Regulatory Information for ANDROID 5
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharm Intl | ANDROID 5 | methyltestosterone | TABLET;BUCCAL | 087222-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
